SEC Form 4 · accession 0001127602-19-003053
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
Jan 28, 2019
Accepted (ET)
Jan 30, 2019 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 28, 2019 | M | 5,000 | $5.45 | A | 133,426 | D | |
| Common StockF1 | Jan 28, 2019 | S | 5,000 | $9.85 | D | 128,426 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy)F1 | $5.45 | Jan 28, 2019 | M | 5,000 | D | Aug 8, 2014 | Aug 8, 2023 | Common Stock | 5,000 | 7,000 | D |
Explanation of responses
- F1The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018.